T2 Biosystems to Present at the Cantor Fitzgerald Global Healthcare Conference
September 18 2017 - 8:00AM
T2 Biosystems, Inc. (NASDAQ:TTOO), an emerging leader in the
development of innovative diagnostic products to improve patient
health, today announced that John McDonough, president and chief
executive officer, and Darlene Deptula-Hicks, SVP and chief
financial officer, are scheduled to attend and present at the
Cantor Fitzgerald Global Healthcare Conference. The conference is
being held September 25-27, 2017 at the InterContinental New York
Barclay Hotel in New York City.
Management is scheduled to present on Monday, September 25, 2017
at 10:55 a.m. ET and will be available for one-on-one meetings
during the conference. The presentation will be webcast live
and available for replay and may be accessed by visiting the
Investors/Events & Presentations section of the Company’s
website at www.t2biosystems.com. A replay of the
webcast will be available shortly after the conclusion of the
presentation and will be archived on the Company's website for 90
days following the presentation.
About T2 Biosystems T2 Biosystems, an emerging
leader in the field of in vitro diagnostics, is dedicated to saving
lives and reducing the cost of healthcare by empowering clinicians
to effectively treat patients faster than ever before. T2
Biosystems is focused on addressing critical unmet needs in
healthcare starting with sepsis, one of the deadliest and most
expensive conditions in hospitals today. The T2Sepsis SolutionTM is
a unique approach that combines the standard of care for the
management of sepsis patients with T2 Biosystems’ products,
including the T2Dx® Instrument and T2Candida® Panel, and the
T2Bacteria® Panel, which is commercially available in Europe and
other countries that accept the CE mark and available for research
use only in the U.S. Powered by the proprietary T2 Magnetic
Resonance technology, or T2MR®, the T2Sepsis Solution is proven to
deliver better patient care and greater cost savings. Hospital
customer experience has demonstrated faster time to effective
treatment, shortened ICU and hospital lengths of stay, reduced use
of unnecessary antifungals, and millions of dollars in savings. T2
Biosystems has an active pipeline of future sepsis products
including additional species and antibiotic resistance, as well as
tests for Lyme disease and hemostasis. For more information, please
visit www.t2biosystems.com.
Company Contact:Darlene Deptula-Hicks, T2
BiosystemsSVP & Chief Financial
Officerddeptula@t2biosystems.com 603-553-5803
Media Contact:Amy Phillips, Feinstein Kean
Healthcare amy.phillips@fkhealth.com 412-327-9499
Investor Contact:Chris Brinzey, Westwicke
Partners chris.brinzey@westwicke.com 339-970-2843
T2 Biosystems (NASDAQ:TTOO)
Historical Stock Chart
From Aug 2024 to Sep 2024
T2 Biosystems (NASDAQ:TTOO)
Historical Stock Chart
From Sep 2023 to Sep 2024